WORLD HEALTH ORGANIZATION **REGIONAL OFFICE FOR EUROPE**

WELTGESUNDHEITSORGANISATION **REGIONALBÜRO FÜR EUROPA**



ORGANISATION MONDIALE DE LA SANTÉ BUREAU RÉGIONAL DE L'EUROPE

ВСЕМИРНАЯ ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ ЕВРОПЕЙСКОЕ РЕГИОНАЛЬНОЕ БЮРО

The Oslo Medicines Initiative: Better access to effective, novel, high-priced medicines – a new vision for collaboration between the public and private sectors

Consultation with non-State actors: Private sector

Virtual meeting 27 April 2021, 11:30–14:30 CEST 31 March 2021 Original: English

Provisional agenda

11:30–11:50 Opening

- Welcome remarks
 - Dr Hans Henri P. Kluge: WHO Regional Director for Europe
 - Dr Bjørn-Inge Larsen: Secretary General, Ministry of Health and Care Services, Norway
 - Dr Natasha Azzopardi Muscat: Director, Division of Country Health Policies and Systems, WHO/Europe

11:50–12:10 Overview of the Oslo Medicines Initiative

- o Dr Audun Hågå: Director General, Norwegian Medicines Agency
- Dr Sarah Garner: Acting Regional Adviser, Access to Medicine and Health Products, WHO/Europe

12:10–13:00 Exchange of views on the substantive themes within the mandate of the Oslo Medicines Initiative

o Chair: Dr Natasha Azzopardi Muscat

Statements and exchange of views by non-State actors, reflecting on the questions posed in the discussion document under the themes of the Oslo Medicines Initiative:

- SOLIDARITY achieving greater solidarity between stakeholders to meet the Sustainable Development Goals and improve access for patients in the WHO European region.
- TRANSPARENCY understanding how transparency can be used to build trust and support access.
- SUSTAINABILITY considering how to ensure a sustainable industry and health care systems.

13:00-13:10 Break

/3

13:10–14:10 Exchange of views on the substantive themes within the mandate of the Oslo Medicines Initiative (continued)

o Chair: Dr Arne-Petter Sanne, Norwegian Directorate of Health

14:10–14:30 Closing session

- Summary of issues and next steps:
 - o Dr Audun Hågå
 - o Dr Sarah Garner
- Chair's closing remarks
 - o Dr Natasha Azzopardi Muscat